Subunit Nanovaccine with Potent Cellular and Mucosal Immunity for COVID-19.
ACS Appl Bio Mater
; 3(9): 5633-5638, 2020 09 21.
Article
in English
| MEDLINE | ID: covidwho-1047923
ABSTRACT
To combat the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic, we formulated the S1 subunit of the virus with two adjuvants, amphiphilic adjuvant monophosphoryl lipid A for Toll-like receptor 4 and CpG oligodeoxynucleotide for Toll-like receptor 9, into cationic liposomes to produce a potent, safer, and translatable nanovaccine. The nanovaccine can efficiently elicit a humoral immune response and strong IgA antibodies in mice. The sera from the vaccinated mice significantly inhibit SARS-CoV-2 from infecting Vero cells. Moreover, relative to the free S1 with a traditional Alum adjuvant, the nanovaccine can elicit strong T-cell immunity by activating both CD4+ and CD8+ cells.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Immunity, Mucosal
/
Nanomedicine
/
COVID-19
Topics:
Vaccines
Limits:
Animals
/
Female
/
Humans
Language:
English
Journal:
ACS Appl Bio Mater
Year:
2020
Document Type:
Article
Affiliation country:
Acsabm.0c00668
Similar
MEDLINE
...
LILACS
LIS